Bli medlem
Bli medlem

Du är här

2020-05-15

Alzinova: Alzinova AB interim report January - March 2020

The Board of Directors and the Chief Executive Officer of Alzinova AB
hereby present the interim report for the first quarter 2020.

Three months (2020-01-01 - 2020-03-31)

· Net sales amounted to SEK 0 (SEK 0).
· Result after financial items amounted to SEK -1,774,906 (SEK
-1,170,594).

· Earnings per share amounted to SEK -0.23 (SEK -0.16).
· Solidity amounted to 91.8% (95.4%).
Significant events during the first quarter of 2020

· The Company announced in January that it had ensured a robust and
validated process to manufacture API that meets the quality standards
required to conduct the clinical trial with the vaccine ALZ-101 on
Alzheimer's disease patients. It was further announced that the study
would commence during the fourth quarter with the initial dosing of
the first patient planned for the turn of the year 2020/2021.

· In February, Alzinova AB made changes to the composition of the
Board of Directors, as Björn Löwenadler stepped down from the board
on personal grounds.

· An extraordinary general meeting was held on 27 February 2020. The
general meeting passed resolutions regarding the number of board
members of the Company and the appointment of Pernilla Sandwall as
new board member.

· In March, Håkan Skogström took up appointment as Chief Financial
Officer.

· Alzinova is actively conducting risk analysis with regard to
covid-19, and is working closely with its partners to reduce any
negative impact of covid-19 to a minimum. Alzinova will provide the
market with relevant and timely updates of significant effects of
covid-19 on Alzinova's operations.

Significant events after the first quarter of 2020

· No significant events.

CEO comments

Our goal is to initiate the first clinical trial with a therapeutic
vaccine that specifically targets the toxic oligomers of amyloid-? in
patients with Alzheimer's disease at the turn of the year, 2020/2021.

The ALZ-101 drug candidate is in late preclinical phase, and during
the first quarter of 2020, we have continued our effort to develop
and manufacture API in order to be able to deliver GMP material and
clinical trial material for the upcoming study in the fall. We have
prepared and worked on the regulatory documentation required to
initiate the clinical phase 1b study on Alzheimer's disease patients
in Finland. This marks the first study with ALZ-101 on humans, and
will thus be a so-called safety study, where the objective is to
demonstrate safety and good tolerability of the therapeutic vaccine
ALZ-101 in Alzheimer's disease patients. In the clinical study, we
will also examine the patients' immune response, as well as a number
of different biological markers that are associated with Alzheimer's
disease.

The drug candidate ALZ-101 and the ALZ-201 antibody differ from
previously tested candidates against Alzheimer's disease, which bind
non-specifically and to differing degrees to various forms of
amyloid-?. Completed clinical trials on other candidates indicate
that the specificity matters, to achieve efficacy as well as to avoid
adverse side effects.

A therapeutic oligomer-specific vaccine against Alzheimer's disease is
specific and unique and entails that the body generates its own
antibodies that target only the toxic oligomers of amyloid-?, which
are believed to be the cause of Alzeimer's disease.

For more information, please contact

Kristina Torfgård, VD

tel: +46 708 46 79 75

E-mail: kristina.torfgard@alzinova.com

Certified Adviser

Corpura Fondkommission AB

E-mail: ca@corpura.se

tel: 0768-532822

Home page: www.corpura.se

This information is information that Alzinova AB is obliged to make
public pursuant to the EU Market Abuse Regulation (MAR). The
information was submitted for publication through the agency of the
contact person set out above at 8:01 CEST on May 15, 2020.

About Alzinova AB

Alzinova AB is engaged in pharmaceutical research and development for
treatment of Alzheimer's disease - one of our major health scourges,
without efficient treatment options. The Company's patented
technology enables the development of novel therapies, that with high
precision could target the substances involved in the formation of
the disease and render them harmless. Alzinova's focus is to develop
a vaccine as a long-acting therapy for treatment and prevention of
Alzheimer's disease. The vaccine is under preclinical development, in
preparation for human clinical trials. Alzinova was founded by
researchers from the MIVAC research center at the University of
Gothenburg, and by GU Ventures AB.

-----------------------------------------------------------
https://news.cision.com/se/alzinova/r/alzinova-ab-interim-report-january...
https://mb.cision.com/Main/13200/3112586/1248140.pdf

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.